福瑞达(600223) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥2,281,769,622.97, a decrease of 34.60% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥192,056,196.93, an increase of 11.00% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥197,826,094.46, reflecting a 19.10% increase compared to the previous year[5]. - The basic earnings per share for Q3 2021 was ¥0.19, up by 11.76% from the same period last year[5]. - For the first nine months of 2021, the company achieved operating revenue of CNY 6.349 billion, a year-on-year decrease of 9.75%, while net profit attributable to the parent company was CNY 503 million, an increase of 21.90%[17]. - The company reported a net profit of CNY 2,219,776,200.30 for the first three quarters of 2021, compared to CNY 1,977,690,578.91 in the same period of 2020, indicating a growth of 12.24%[38]. - Net profit for the first three quarters of 2021 was ¥496,566,708.16, compared to ¥461,757,402.41 in 2020, indicating an increase of about 7.5%[42]. - The total profit for the first three quarters of 2021 was ¥642,404,193.40, slightly higher than ¥633,337,852.75 in 2020, reflecting a growth of approximately 1.6%[42]. - Basic earnings per share for the first three quarters of 2021 were ¥0.50, compared to ¥0.41 in the same period of 2020, marking an increase of 21.9%[44]. Assets and Liabilities - The total assets at the end of the reporting period were ¥63,628,537,354.90, an increase of 3.46% compared to the end of the previous year[8]. - As of September 30, 2021, the company reported total assets of CNY 63.629 billion, with net assets attributable to the parent company at CNY 4.326 billion, reflecting growth of 3.46% and 6.02% respectively since the beginning of the year[17]. - The total liabilities as of September 30, 2021, were CNY 57,446,512,828.44, compared to CNY 54,981,173,661.44 at the end of 2020, indicating an increase of 8.48%[38]. - The equity attributable to shareholders of the parent company increased to CNY 4,325,768,512.82 as of September 30, 2021, from CNY 4,080,050,127.32 at the end of 2020, reflecting a rise of 6.02%[38]. - The company's total liabilities increased by CNY 4,465,339,167.00 from the end of 2020 to September 30, 2021, reflecting a significant rise in financial obligations[35]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥4,803,700,841.44, showing a significant increase of 209.62%[5]. - Cash flow from operating activities for the first three quarters of 2021 was ¥4,803,700,841.44, significantly higher than ¥1,551,488,268.89 in 2020, showing an increase of approximately 209.5%[47]. - The net cash flow from investment activities for the first three quarters of 2021 was -¥273,222,403.57, compared to -¥100,095,270.36 in 2020, indicating a worsening of investment cash flow[48]. - The company experienced a credit impairment loss of -¥45,715,780.80 in the first three quarters of 2021, contrasting with a gain of ¥30,961,529.35 in 2020[42]. - The company's short-term borrowings rose to CNY 4,499,674,450.03 as of September 30, 2021, up from CNY 4,303,297,457.12 at the end of 2020, an increase of 4.56%[35]. Segment Performance - The health real estate segment recorded a signed amount of CNY 11.744 billion, up 11.05% year-on-year, but operating revenue decreased by 25.80% to CNY 4.250 billion, with a gross margin of 22.23%[17]. - The cosmetics segment saw operating revenue of CNY 999 million, a significant increase of 174.58% year-on-year, with a gross margin of 63.21%[20]. - The pharmaceutical segment reported operating revenue of CNY 396 million, up 22.14% year-on-year, with a gross margin of 58.32%[20]. - The raw materials and additives segment achieved operating revenue of CNY 176 million, reflecting a year-on-year growth of 35.26%, with a gross margin of 40%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,075[12]. - The largest shareholder, Shandong Commercial Group Co., Ltd., held 52.00% of the shares[12]. - The company’s major shareholder, Shandong Commercial Group, holds 52.00% of the total shares, with 50.02% held through its own account and 1.98% through a pledged account[16]. Strategic Initiatives - The company plans to introduce strategic investors through a public offering for its wholly-owned subsidiary, Shandong Furuida Biotechnology Co., Ltd., with the offering period from September 24 to November 23, 2021[23]. - The company adjusted the exercise price of its stock option incentive plan, reducing it from CNY 2.67 to CNY 2.47 per share for the first grant[22].